MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
stock under equity...
$69K
Net cash provided by
financing activities
$69K
Net decrease in cash
and cash...
-$110,016K
Canceled cashflow
$69K
Share-based compensation
expense
$8,416K
Operating lease
liabilities
$3,778K
Accounts payable
$2,026K
Operating lease
right-of-use and other...
-$689K
Depreciation expense
$355K
Other long-term
liabilities
$204K
Non-cash interest
expense
$106K
Maturities of short-term
investments
$147,498K
Net cash used in
operating activities
-$85,854K
Net cash used in
investing activities
-$24,231K
Canceled cashflow
$15,574K
Canceled cashflow
$147,498K
Net loss
-$73,333K
Accrued expenses and
other current...
-$16,216K
Purchases of short-term
investments
$171,601K
Contract liabilities
-$9,443K
Amortization of premium and
accretion of discounts on...
$900K
Prepaid expenses and
other current assets
$562K
Accounts receivable, net
$544K
Inventory
$430K
Purchases of property and
equipment
$128K
Back
Back
Cash Flow
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)
source: myfinsight.com